https://viridian.comocreative.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-development-for-thyroid-eye-disease-ted-pharmacodynamic-responses-in-healthy-volunteers-and-patients-with-active-ted/ 2023-09-28T16:11:32+00:00 https://viridian.comocreative.com/document/durability-of-treatment-response-with-vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-patients-with-thyroid-eye-disease-ted-phase-1-2-clinical-study-2/ 2023-09-28T16:13:31+00:00 https://viridian.comocreative.com/document/preclinical-pharmacokinetics-and-clinical-exposure-prediction-for-vrdn-003-a-next-generation-half-life-extended-antibody-to-the-igf-1-receptor-for-thyroid-eye-disease-ted/ 2023-09-28T16:15:28+00:00 https://viridian.comocreative.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-vitro-pharmacology-and-phase-1-2-results-in-patients-with-thyroid-eye-disease-ted/ 2023-09-28T16:16:42+00:00 https://viridian.comocreative.com/document/in-vitro-pharmacology-and-phase-1-2-results-of-vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-for-thyroid-eye-disease-ted/ 2023-09-28T16:18:23+00:00 https://viridian.comocreative.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1r-proof-of-concept-results-in-chronic-ted/ 2023-09-28T16:19:25+00:00 https://viridian.comocreative.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-development-for-thyroid-eye-disease-ted-binds-to-a-distinct-epitope-from-teprotumumab/ 2023-10-11T19:45:32+00:00 https://viridian.comocreative.com/document/durability-of-treatment-response-with-vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-patients-with-thyroid-eye-disease-ted-phase-1-2-clinical-study/ 2023-10-11T19:46:58+00:00 https://viridian.comocreative.com/document/phase-1-2-trial-of-vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-patients-with-thyroid-eye-disease-ted/ 2023-10-11T19:47:19+00:00 https://viridian.comocreative.com/document/vrdn-002-a-next-generation-half-life-extended-antagonist-antibody-to-igf-1-receptor-for-thyroid-eye-disease-ted-safety-and-pharmacokinetic-pharmacodynamic-pk-pd-results-in-healthy-volunteers/ 2023-10-11T19:48:21+00:00 https://viridian.comocreative.com/document/preclinical-pharmacokinetics-and-bioavailability-of-vrdn-002-a-next-generation-half-life-extended-antagonist-antibody-to-the-igf-1-receptor-for-thyroid-eye-disease-ted/ 2023-10-11T19:49:24+00:00 https://viridian.comocreative.com/document/preclinical-pharmacokinetics-of-vrdn-003-a-next-generation-half-life-extended-antibody-to-the-igf-1-receptor-for-thyroid-eye-disease/ 2023-10-11T19:49:49+00:00 https://viridian.comocreative.com/document/design-and-preclinical-characterization-of-vrdn-003-a-next-generation-half-life-extended-antibody-to-igf-1r-in-development-for-thyroid-eye-disease-ted/ 2023-10-11T19:50:11+00:00 https://viridian.comocreative.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-for-thyroid-eye-disease-ted-phase-1-2-clinical-study-in-patients/ 2023-10-11T19:51:24+00:00 https://viridian.comocreative.com/document/thrive-phase-3-trial-of-vrdn-001-a-full-antagonist-antibody-to-the-igf-1-receptor-for-thyroid-eye-disease-ted/ 2023-10-11T19:51:38+00:00 https://viridian.comocreative.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-development-for-thyroid-eye-disease-ted-interim-phase-1-2-pharmacodynamic-results/ 2023-10-11T19:52:20+00:00 https://viridian.comocreative.com/document/vrdn-002-a-novel-antagonist-antibody-to-igf-1-receptor-for-thyroid-eye-disease-ted-results-of-a-phase-1-trial/ 2023-10-11T19:52:44+00:00 https://viridian.comocreative.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1r-in-development-for-thyroid-eye-disease-ted-binds-to-a-distinct-epitope-from-teprotumumab/ 2023-10-11T19:54:43+00:00 https://viridian.comocreative.com/document/vrdn-001-a-full-antagonist-antibody-to-the-insulin-like-growth-factor-1-receptor-igf-1r-for-thyroid-eye-disease-ted-phase-1-2-proof-of-concept-in-patients-with-ted/ 2023-10-11T19:57:34+00:00 https://viridian.comocreative.com/document/vrdn-001-a-full-antagonist-antibody-to-the-insulin-like-growth-factor-1-receptor-igf-1r-for-thyroid-eye-disease-ted-binds-to-a-distinct-epitope-from-teprotumumab/ 2023-10-11T19:57:42+00:00 https://viridian.comocreative.com/document/vrdn-001-a-potent-and-selective-insulin-like-growth-factor-1-receptor-igf-1r-antagonist-antibody-for-thyroid-eye-disease-ted-phase-1-safety-and-pharmacodynamic-results-in-healthy-volunteers/ 2023-10-11T19:58:24+00:00 https://viridian.comocreative.com/document/characterization-of-vrdn-001-a-high-affinity-and-potent-anti-igf-1r-inhibitory-antibody-for-the-treatment-of-thyroid-eye-disease/ 2023-10-11T20:00:03+00:00 https://viridian.comocreative.com/document/vrdn-002-a-second-generation-insulin-like-growth-factor-1-receptor-igf-1r-antibody-for-ted-preclinical-pk-profile-and-clinical-promise/ 2023-10-11T20:00:12+00:00